zuranolone

Sage lays off 40%, shakes up C-suite to squeeze a profit out of partially rejected zuranolone
Sage lays off 40%, shakes up C-suite to squeeze a profit out of partially rejected zuranolone
Fierce Biotech
SAGE Therapeutics
layoffs
Biogen
major depressive disorcer
zuranolone
Flag link:
The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
The Neuropsychiatric Pipeline: 10 Late-Stage Therapies to Watch
BioSpace
depression
Biogen
SAGE Therapeutics
zuranolone
Intra-Cellular Therapies
lumateperone
Alto Neuroscience
ALTO-100
schizophrenia
Karuna Therapeutics
KarXT
Cerevel Therapeutics
emraclidine
Acadia Pharmaceuticals
pimavanserin
Axesome Therapeutics
AXS-05
Alzheimer's agitation
NRx
NRX-101
bipolar disorder
Biohaven
troriluzole
OCD
VistaGen
fasedienol
social anxiety
Flag link:
FDA Approves Biogen, Sage’s Zurzuvae as First Pill for Postpartum Depression
FDA Approves Biogen, Sage’s Zurzuvae as First Pill for Postpartum Depression
BioSpace
Biogen
SAGE Therapeutics
FDA
Zurzuvae
postpartum depression
major depressive disorder
zuranolone
Flag link:
FDA Action Alert: Mesoblast, Sage/Biogen and Galera
FDA Action Alert: Mesoblast, Sage/Biogen and Galera
BioSpace
FDA
graft vs host disease
head and neck cancer
postpartum depression
major depressive disorder
Mesoblast
remestemcel-L
Biogen
SAGE Therapeutics
zuranolone
Galera Therapeutics
avasopasem manganese
Flag link:
Go or no go? Biogen and Astellas head towards key PDUFAs
Go or no go? Biogen and Astellas head towards key PDUFAs
EP Vantage
FDA
Astellas
Zimura
Biogen
SAGE Therapeutics
zuranolone
major depressive disorder
postpartum depression
geographic atrophy
Flag link:
Sage Stock Drops Despite Promising Phase III Depression Data
Sage Stock Drops Despite Promising Phase III Depression Data
BioSpace
SAGE Therapeutics
zuranolone
Biogen
depression
Flag link:
9 Highly Anticipated FDA Decisions in Second Half of 2023
9 Highly Anticipated FDA Decisions in Second Half of 2023
BioSpace
FDA
Eisai
Biogen
Leqembi
Alzheimer's disease
SAGE Therapeutics
zuranolone
postpartum depression
major depressive disorder
Roche
Tecentriq
non-small cell lung cancer
CRISPR Therapeutics
Bluebird Bio
lovo-cel
exa-cel
BrainStorm Cell Therapeutics
NurOwn
Flag link:
5 FDA decisions to watch in the third quarter
5 FDA decisions to watch in the third quarter
BioPharma Dive
FDA
SAGE Therapeutics
Biogen
zuranolone
Eisai
Leqembi
Sanofi
AstraZeneca
nirsevimab
Iveric Bio
Zimura
Alnylam
Onpattro
Flag link:
FDA says no adcomm planned for Biogen, Sage's depression drug
FDA says no adcomm planned for Biogen, Sage's depression drug
Seeking Alpha
Biogen
SAGE Therapeutics
FDA
zuranolone
major depressive disorder
postpartum depression
Flag link:
Biogen, Sage Get FDA Priority Review of Zuranolone
Biogen, Sage Get FDA Priority Review of Zuranolone
Marketwatch
Biogen
SAGE Therapeutics
FDA
zuranolone
priority review
postpartum depression
major depressive disorder
Flag link:
Sage, Biogen post fresh phase 3 depression data as FDA filing nears completion
Sage, Biogen post fresh phase 3 depression data as FDA filing nears completion
Fierce Biotech
SAGE Therapeutics
Biogen
zuranolone
postpartum depression
clinical trials
Flag link:
Ahead of FDA filing, Sage and Biogen tout more data in hopes of alleviating durability concerns
Ahead of FDA filing, Sage and Biogen tout more data in hopes of alleviating durability concerns
Endpoints
SAGE Therapeutics
Biogen
major depressive disorder
zuranolone
Flag link:
Sage, Biogen drug meets goal in postpartum depression study
Sage, Biogen drug meets goal in postpartum depression study
BioPharma Dive
SAGE Therapeutics
Biogen
FDA
zuranolone
postpartum depression
Flag link:
Sage, Biogen get rolling on FDA submission for depression med
Sage, Biogen get rolling on FDA submission for depression med
Fierce Biotech
SAGE Therapeutics
Biogen
zuranolone
FDA
major depressive disorder
Flag link:
Sage claims new data show depression drug works, but doubts remain
Sage claims new data show depression drug works, but doubts remain
Biopharma Dive
SAGE Therapeutics
Biogen
depression
clinical trials
zuranolone
Flag link:
Where Will Biogen Be in 5 Years?
Where Will Biogen Be in 5 Years?
Motley Fool
Biogen
Aduhelm
zuranolone
BIIB115
lecanemab
Flag link:
Sage changes primary endpoint in key study months after analysts fret about depression drug's durability
Sage changes primary endpoint in key study months after analysts fret about depression drug's durability
Endpoints
SAGE Therapeutics
clinical trials
zuranolone
depression
endpoints
SSRIs
Flag link:
Biogen, Sage plot 2022 filing for zuranolone approval, furthering turnaround of depression drug
Biogen, Sage plot 2022 filing for zuranolone approval, furthering turnaround of depression drug
Fierce Biotech
Biogen
SAGE Therapeutics
zuranolone
FDA
clinical depression
Flag link:
Biogen and Sage Present Positive Data for Breakthrough Depression Therapy
Biogen and Sage Present Positive Data for Breakthrough Depression Therapy
BioSpace
Biogen
SAGE Therapeutics
major depressive disorder
postpartum depression
clinical trials
zuranolone
Flag link:
Could These 3 Potential Blockbusters Transform Biogen?
Could These 3 Potential Blockbusters Transform Biogen?
Motley Fool
Biogen
zuranolone
depression
TMS-007
stroke
Aduhelm
Alzheimer's disease
Flag link:

Pages